schliessen

Filtern

 

Bibliotheken

Cover Image

Effect of low dose tamoxifen on the insulin-like growth factor system in healthy women

The use of tamoxifen as a preventive agent may be limited by the increased risk of endometrial cancer and venous thromboembolic events observed in postmenopausal women. We have recently shown a comparable activity of lower doses of tamoxifen on several surrogate biomarkers of cardiovascular disease... Full description

Journal Title: Breast cancer research and treatment 2001, Vol.69 (1), p.21-27
Main Author: BONANNI, Bernardo
Other Authors: JOHANSSON, Harriet , DECENSI, Andrea , GANDINI, Sara , GUERRIERI-GONZAGA, Aliana , TORRISI, Rosalba , SANDRI, Maria Teresa , CAZZANIGA, Massimiliano , MORA, Serena , ROBERTSON, Chris , LIEN, Ernst Asbjorn
Format: Electronic Article Electronic Article
Language: English
Subjects:
Anticarcinogenic Agents - administration & dosage
Anticarcinogenic Agents - pharmacology
Antineoplastic agents
Biological and medical sciences
Biomarkers, Tumor - analysis
Breast Neoplasms - prevention & control
Dose-Response Relationship, Drug
Female
General aspects
Humans
Insulin-Like Growth Factor I - analysis
Insulin-Like Growth Factor I - biosynthesis
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Placebos
Tamoxifen - administration & dosage
Tamoxifen - pharmacology
Publisher: Dordrecht: Springer
ID: ISSN: 0167-6806
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_72332041
title: Effect of low dose tamoxifen on the insulin-like growth factor system in healthy women
format: Article
creator:
  • BONANNI, Bernardo
  • JOHANSSON, Harriet
  • DECENSI, Andrea
  • GANDINI, Sara
  • GUERRIERI-GONZAGA, Aliana
  • TORRISI, Rosalba
  • SANDRI, Maria Teresa
  • CAZZANIGA, Massimiliano
  • MORA, Serena
  • ROBERTSON, Chris
  • LIEN, Ernst Asbjorn
subjects:
  • Anticarcinogenic Agents - administration & dosage
  • Anticarcinogenic Agents - pharmacology
  • Antineoplastic agents
  • Biological and medical sciences
  • Biomarkers, Tumor - analysis
  • Breast Neoplasms - prevention & control
  • Dose-Response Relationship, Drug
  • Female
  • General aspects
  • Humans
  • Insulin-Like Growth Factor I - analysis
  • Insulin-Like Growth Factor I - biosynthesis
  • Medical sciences
  • Middle Aged
  • Pharmacology. Drug treatments
  • Placebos
  • Tamoxifen - administration & dosage
  • Tamoxifen - pharmacology
ispartof: Breast cancer research and treatment, 2001, Vol.69 (1), p.21-27
description: The use of tamoxifen as a preventive agent may be limited by the increased risk of endometrial cancer and venous thromboembolic events observed in postmenopausal women. We have recently shown a comparable activity of lower doses of tamoxifen on several surrogate biomarkers of cardiovascular disease and breast cancer, including Insulin-like Growth Factor-I (IGF-I). To provide further insight into the effect of tamoxifen at low doses on the IGF system, we have correlated the drug serum levels attained after 2 months of either placebo (n = 32), tamoxifen 20 mg/day (n = 26), 10 mg/day (n = 23) or 10 mg/every other day (n = 29) with the changes in IGF-I, Insulin-like Growth Factor-II (IGF-II), Insulin-like Growth Factor Binding Protein-1 (IGFBP-1), Insulin-like Growth Factor Binding Protein-3 (IGFBP-3), and IGF-I/IGFBP-3 ratio. Compared with placebo, tamoxifen induced a mean +/- standard error (SE) reduction of IGF-I of 16.9 +/- 7.8%, p < 0.05, a non-significant increase of 22.9 +/- 12.2% in IGF-II, an increase in IGFBP-1 of 49.3 +/- 22.7%, p < 0.05, and a non-significant change of IGFBP-3 (-4.0% +/- 9.2). No significant concentration-response relationship was observed between serum tamoxifen concentrations and the biomarker changes except for the ratio of IGF-I/IGFBP-3, which decreased by 1.53 +/- 0.68% for any increase by 10 ng/ml of serum tamoxifen concentration (p = 0.02). Although low tamoxifen concentrations induce a comparable modulation of the IGF family relative to the conventional dose, the lower decrements in the IGF-I/IGFBP-3 ratio observed at low drug concentrations might be associated with a reduced preventive activity. Further studies on the search of the minimal active dose of tamoxifen are warranted.
language: eng
source:
identifier: ISSN: 0167-6806
fulltext: no_fulltext
issn:
  • 0167-6806
  • 1573-7217
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.0587797
LOCALfalse
PrimoNMBib
record
control
sourceidproquest_cross
recordidTN_cdi_proquest_miscellaneous_72332041
sourceformatXML
sourcesystemPC
sourcerecordid72332041
originalsourceidFETCH-LOGICAL-c295t-d14998cdcfe104356db101d54c066ac938f4aa4a4fbcb2b0509f39b338047bc70
addsrcrecordideNpd0E1P3DAQBmALFcFCOfeGrErlFpjxRxxzWyG-JCQu0GvkOHY3kMRgO9ruvyeIlRCc5vLMq5mXkF8IpwiMny3PEZAxgRKkQrVDFigVLxRD9YMsAEtVlBWU--QgpScA0Ar0HtlHVFJXTC7I30vvnc00eNqHNW1DcjSbIfzvvBtpGGleOdqNaeq7sei7Z0f_xbDOK-qNzSHStEnZDbOgK2f6vNrQdRjc-JPsetMnd7Sdh-Tx6vLh4qa4u7--vVjeFZZpmYsWhdaVba13CILLsm3mf1opLJSlsZpXXhgjjPCNbVgDErTnuuG8AqEaq-CQnHzkvsTwOrmU66FL1vW9GV2YUq0Y5wwEzvD3N_gUpjjOt9UMmRAl53JGZx_IxpBSdL5-id1g4qZGqN_7rpf1l77njeNt7NQMrv3024Jn8GcLTLKm99GMtkufTkCFrKrgDd0fhrU
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid212446335
display
typearticle
titleEffect of low dose tamoxifen on the insulin-like growth factor system in healthy women
creatorBONANNI, Bernardo ; JOHANSSON, Harriet ; DECENSI, Andrea ; GANDINI, Sara ; GUERRIERI-GONZAGA, Aliana ; TORRISI, Rosalba ; SANDRI, Maria Teresa ; CAZZANIGA, Massimiliano ; MORA, Serena ; ROBERTSON, Chris ; LIEN, Ernst Asbjorn
creatorcontribBONANNI, Bernardo ; JOHANSSON, Harriet ; DECENSI, Andrea ; GANDINI, Sara ; GUERRIERI-GONZAGA, Aliana ; TORRISI, Rosalba ; SANDRI, Maria Teresa ; CAZZANIGA, Massimiliano ; MORA, Serena ; ROBERTSON, Chris ; LIEN, Ernst Asbjorn
descriptionThe use of tamoxifen as a preventive agent may be limited by the increased risk of endometrial cancer and venous thromboembolic events observed in postmenopausal women. We have recently shown a comparable activity of lower doses of tamoxifen on several surrogate biomarkers of cardiovascular disease and breast cancer, including Insulin-like Growth Factor-I (IGF-I). To provide further insight into the effect of tamoxifen at low doses on the IGF system, we have correlated the drug serum levels attained after 2 months of either placebo (n = 32), tamoxifen 20 mg/day (n = 26), 10 mg/day (n = 23) or 10 mg/every other day (n = 29) with the changes in IGF-I, Insulin-like Growth Factor-II (IGF-II), Insulin-like Growth Factor Binding Protein-1 (IGFBP-1), Insulin-like Growth Factor Binding Protein-3 (IGFBP-3), and IGF-I/IGFBP-3 ratio. Compared with placebo, tamoxifen induced a mean +/- standard error (SE) reduction of IGF-I of 16.9 +/- 7.8%, p < 0.05, a non-significant increase of 22.9 +/- 12.2% in IGF-II, an increase in IGFBP-1 of 49.3 +/- 22.7%, p < 0.05, and a non-significant change of IGFBP-3 (-4.0% +/- 9.2). No significant concentration-response relationship was observed between serum tamoxifen concentrations and the biomarker changes except for the ratio of IGF-I/IGFBP-3, which decreased by 1.53 +/- 0.68% for any increase by 10 ng/ml of serum tamoxifen concentration (p = 0.02). Although low tamoxifen concentrations induce a comparable modulation of the IGF family relative to the conventional dose, the lower decrements in the IGF-I/IGFBP-3 ratio observed at low drug concentrations might be associated with a reduced preventive activity. Further studies on the search of the minimal active dose of tamoxifen are warranted.
identifier
0ISSN: 0167-6806
1EISSN: 1573-7217
2DOI: 10.1023/A:1012241505717
3PMID: 11759825
4CODEN: BCTRD6
languageeng
publisherDordrecht: Springer
subjectAnticarcinogenic Agents - administration & dosage ; Anticarcinogenic Agents - pharmacology ; Antineoplastic agents ; Biological and medical sciences ; Biomarkers, Tumor - analysis ; Breast Neoplasms - prevention & control ; Dose-Response Relationship, Drug ; Female ; General aspects ; Humans ; Insulin-Like Growth Factor I - analysis ; Insulin-Like Growth Factor I - biosynthesis ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Placebos ; Tamoxifen - administration & dosage ; Tamoxifen - pharmacology
ispartofBreast cancer research and treatment, 2001, Vol.69 (1), p.21-27
rights
02002 INIST-CNRS
1Copyright Kluwer Academic Publishers Sep 2001
lds50peer_reviewed
citesFETCH-LOGICAL-c295t-d14998cdcfe104356db101d54c066ac938f4aa4a4fbcb2b0509f39b338047bc70
links
openurl$$Topenurl_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14081288$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11759825$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0BONANNI, Bernardo
1JOHANSSON, Harriet
2DECENSI, Andrea
3GANDINI, Sara
4GUERRIERI-GONZAGA, Aliana
5TORRISI, Rosalba
6SANDRI, Maria Teresa
7CAZZANIGA, Massimiliano
8MORA, Serena
9ROBERTSON, Chris
10LIEN, Ernst Asbjorn
title
0Effect of low dose tamoxifen on the insulin-like growth factor system in healthy women
1Breast cancer research and treatment
addtitleBreast Cancer Res Treat
descriptionThe use of tamoxifen as a preventive agent may be limited by the increased risk of endometrial cancer and venous thromboembolic events observed in postmenopausal women. We have recently shown a comparable activity of lower doses of tamoxifen on several surrogate biomarkers of cardiovascular disease and breast cancer, including Insulin-like Growth Factor-I (IGF-I). To provide further insight into the effect of tamoxifen at low doses on the IGF system, we have correlated the drug serum levels attained after 2 months of either placebo (n = 32), tamoxifen 20 mg/day (n = 26), 10 mg/day (n = 23) or 10 mg/every other day (n = 29) with the changes in IGF-I, Insulin-like Growth Factor-II (IGF-II), Insulin-like Growth Factor Binding Protein-1 (IGFBP-1), Insulin-like Growth Factor Binding Protein-3 (IGFBP-3), and IGF-I/IGFBP-3 ratio. Compared with placebo, tamoxifen induced a mean +/- standard error (SE) reduction of IGF-I of 16.9 +/- 7.8%, p < 0.05, a non-significant increase of 22.9 +/- 12.2% in IGF-II, an increase in IGFBP-1 of 49.3 +/- 22.7%, p < 0.05, and a non-significant change of IGFBP-3 (-4.0% +/- 9.2). No significant concentration-response relationship was observed between serum tamoxifen concentrations and the biomarker changes except for the ratio of IGF-I/IGFBP-3, which decreased by 1.53 +/- 0.68% for any increase by 10 ng/ml of serum tamoxifen concentration (p = 0.02). Although low tamoxifen concentrations induce a comparable modulation of the IGF family relative to the conventional dose, the lower decrements in the IGF-I/IGFBP-3 ratio observed at low drug concentrations might be associated with a reduced preventive activity. Further studies on the search of the minimal active dose of tamoxifen are warranted.
subject
0Anticarcinogenic Agents - administration & dosage
1Anticarcinogenic Agents - pharmacology
2Antineoplastic agents
3Biological and medical sciences
4Biomarkers, Tumor - analysis
5Breast Neoplasms - prevention & control
6Dose-Response Relationship, Drug
7Female
8General aspects
9Humans
10Insulin-Like Growth Factor I - analysis
11Insulin-Like Growth Factor I - biosynthesis
12Medical sciences
13Middle Aged
14Pharmacology. Drug treatments
15Placebos
16Tamoxifen - administration & dosage
17Tamoxifen - pharmacology
issn
00167-6806
11573-7217
fulltextfalse
rsrctypearticle
creationdate2001
recordtypearticle
recordideNpd0E1P3DAQBmALFcFCOfeGrErlFpjxRxxzWyG-JCQu0GvkOHY3kMRgO9ruvyeIlRCc5vLMq5mXkF8IpwiMny3PEZAxgRKkQrVDFigVLxRD9YMsAEtVlBWU--QgpScA0Ar0HtlHVFJXTC7I30vvnc00eNqHNW1DcjSbIfzvvBtpGGleOdqNaeq7sei7Z0f_xbDOK-qNzSHStEnZDbOgK2f6vNrQdRjc-JPsetMnd7Sdh-Tx6vLh4qa4u7--vVjeFZZpmYsWhdaVba13CILLsm3mf1opLJSlsZpXXhgjjPCNbVgDErTnuuG8AqEaq-CQnHzkvsTwOrmU66FL1vW9GV2YUq0Y5wwEzvD3N_gUpjjOt9UMmRAl53JGZx_IxpBSdL5-id1g4qZGqN_7rpf1l77njeNt7NQMrv3024Jn8GcLTLKm99GMtkufTkCFrKrgDd0fhrU
startdate2001
enddate2001
creator
0BONANNI, Bernardo
1JOHANSSON, Harriet
2DECENSI, Andrea
3GANDINI, Sara
4GUERRIERI-GONZAGA, Aliana
5TORRISI, Rosalba
6SANDRI, Maria Teresa
7CAZZANIGA, Massimiliano
8MORA, Serena
9ROBERTSON, Chris
10LIEN, Ernst Asbjorn
general
0Springer
1Springer Nature B.V
scope
0IQODW
1CGR
2CUY
3CVF
4ECM
5EIF
6NPM
7AAYXX
8CITATION
93V.
107TO
117X7
127XB
1388E
148AO
158C1
168FI
178FJ
188FK
198G5
20ABUWG
21AZQEC
22BENPR
23DWQXO
24FYUFA
25GHDGH
26GNUQQ
27GUQSH
28H94
29K9-
30K9.
31M0R
32M0S
33M1P
34M2O
35MBDVC
36PADUT
37PQEST
38PQQKQ
39PQUKI
40PRINS
41Q9U
427X8
sort
creationdate2001
titleEffect of low dose tamoxifen on the insulin-like growth factor system in healthy women
authorBONANNI, Bernardo ; JOHANSSON, Harriet ; DECENSI, Andrea ; GANDINI, Sara ; GUERRIERI-GONZAGA, Aliana ; TORRISI, Rosalba ; SANDRI, Maria Teresa ; CAZZANIGA, Massimiliano ; MORA, Serena ; ROBERTSON, Chris ; LIEN, Ernst Asbjorn
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-c295t-d14998cdcfe104356db101d54c066ac938f4aa4a4fbcb2b0509f39b338047bc70
rsrctypearticles
prefilterarticles
languageeng
creationdate2001
topic
0Anticarcinogenic Agents - administration & dosage
1Anticarcinogenic Agents - pharmacology
2Antineoplastic agents
3Biological and medical sciences
4Biomarkers, Tumor - analysis
5Breast Neoplasms - prevention & control
6Dose-Response Relationship, Drug
7Female
8General aspects
9Humans
10Insulin-Like Growth Factor I - analysis
11Insulin-Like Growth Factor I - biosynthesis
12Medical sciences
13Middle Aged
14Pharmacology. Drug treatments
15Placebos
16Tamoxifen - administration & dosage
17Tamoxifen - pharmacology
toplevelpeer_reviewed
creatorcontrib
0BONANNI, Bernardo
1JOHANSSON, Harriet
2DECENSI, Andrea
3GANDINI, Sara
4GUERRIERI-GONZAGA, Aliana
5TORRISI, Rosalba
6SANDRI, Maria Teresa
7CAZZANIGA, Massimiliano
8MORA, Serena
9ROBERTSON, Chris
10LIEN, Ernst Asbjorn
collection
0Pascal-Francis
1Medline
2MEDLINE
3MEDLINE (Ovid)
4MEDLINE
5MEDLINE
6PubMed
7CrossRef
8ProQuest Central (Corporate)
9Oncogenes and Growth Factors Abstracts
10Health & Medical Collection
11ProQuest Central (purchase pre-March 2016)
12Medical Database (Alumni Edition)
13ProQuest Pharma Collection
14Public Health Database
15Hospital Premium Collection
16Hospital Premium Collection (Alumni Edition)
17ProQuest Central (Alumni) (purchase pre-March 2016)
18Research Library (Alumni Edition)
19ProQuest Central (Alumni Edition)
20ProQuest Central Essentials
21ProQuest Central
22ProQuest Central Korea
23Health Research Premium Collection
24Health Research Premium Collection (Alumni)
25ProQuest Central Student
26Research Library Prep
27AIDS and Cancer Research Abstracts
28Consumer Health Database (Alumni Edition)
29ProQuest Health & Medical Complete (Alumni)
30Consumer Health Database
31Health & Medical Collection (Alumni Edition)
32Medical Database
33Research Library
34Research Library (Corporate)
35Research Library China
36ProQuest One Academic Eastern Edition
37ProQuest One Academic
38ProQuest One Academic UKI Edition
39ProQuest Central China
40ProQuest Central Basic
41MEDLINE - Academic
jtitleBreast cancer research and treatment
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0BONANNI, Bernardo
1JOHANSSON, Harriet
2DECENSI, Andrea
3GANDINI, Sara
4GUERRIERI-GONZAGA, Aliana
5TORRISI, Rosalba
6SANDRI, Maria Teresa
7CAZZANIGA, Massimiliano
8MORA, Serena
9ROBERTSON, Chris
10LIEN, Ernst Asbjorn
formatjournal
genrearticle
ristypeJOUR
atitleEffect of low dose tamoxifen on the insulin-like growth factor system in healthy women
jtitleBreast cancer research and treatment
addtitleBreast Cancer Res Treat
date2001
risdate2001
volume69
issue1
spage21
epage27
pages21-27
issn0167-6806
eissn1573-7217
codenBCTRD6
abstractThe use of tamoxifen as a preventive agent may be limited by the increased risk of endometrial cancer and venous thromboembolic events observed in postmenopausal women. We have recently shown a comparable activity of lower doses of tamoxifen on several surrogate biomarkers of cardiovascular disease and breast cancer, including Insulin-like Growth Factor-I (IGF-I). To provide further insight into the effect of tamoxifen at low doses on the IGF system, we have correlated the drug serum levels attained after 2 months of either placebo (n = 32), tamoxifen 20 mg/day (n = 26), 10 mg/day (n = 23) or 10 mg/every other day (n = 29) with the changes in IGF-I, Insulin-like Growth Factor-II (IGF-II), Insulin-like Growth Factor Binding Protein-1 (IGFBP-1), Insulin-like Growth Factor Binding Protein-3 (IGFBP-3), and IGF-I/IGFBP-3 ratio. Compared with placebo, tamoxifen induced a mean +/- standard error (SE) reduction of IGF-I of 16.9 +/- 7.8%, p < 0.05, a non-significant increase of 22.9 +/- 12.2% in IGF-II, an increase in IGFBP-1 of 49.3 +/- 22.7%, p < 0.05, and a non-significant change of IGFBP-3 (-4.0% +/- 9.2). No significant concentration-response relationship was observed between serum tamoxifen concentrations and the biomarker changes except for the ratio of IGF-I/IGFBP-3, which decreased by 1.53 +/- 0.68% for any increase by 10 ng/ml of serum tamoxifen concentration (p = 0.02). Although low tamoxifen concentrations induce a comparable modulation of the IGF family relative to the conventional dose, the lower decrements in the IGF-I/IGFBP-3 ratio observed at low drug concentrations might be associated with a reduced preventive activity. Further studies on the search of the minimal active dose of tamoxifen are warranted.
copDordrecht
pubSpringer
pmid11759825
doi10.1023/A:1012241505717